Enveda, an AI drugmaker, banks $311M in venture funding

🇺🇸 BioPharma Dive (US) —

AI Summary

Enveda, a US-based AI-driven drugmaker, secured $311 million in venture funding to develop drug candidates derived from plants and microbes. The company currently has three drug candidates in human testing targeting immune diseases and obesity.

Enveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for immune diseases and obesity.

Markets Deals Health AI & Tech AI drug discovery venture funding immune diseases obesity drug candidates biotechnology United States

Read original source →